Mira Meriluoto, Lea Hedman, Laura Tanner, Ville Simell, Marjaana Mäkinen, Satu Simell, Juha Mykkänen, Jan Korpelainen, Olli Ruuskanen, Jorma Ilonen, Mikael Knip, Olli Simell, Klaus Hedman, and Maria Söderlund-Venermo
Author affiliations: University of Helsinki, Helsinki, Finland (M. Meriluoto, L. Hedman, M. Knip, K. Hedman, M. Söderlund-Venermo); Helsinki University Central Hospital, Helsinki (L. Hedman, M. Knip, K. Hedman); University of Turku, Turku, Finland (L. Tanner, V. Simell, M. Mäkinen, S. Simell, J. Mykkänen, J. Korpelainen, O. Ruuskanen, J. Ilonen, O. Simell); University of Eastern Finland, Kuopio, Finland (J. Ilonen); Tampere University Hospital, Tampere, Finland (M. Knip); Folkhälsan Research Center, Helsinki (M. Knip)
To the Editor: In our earlier assessment of the etiologic role of human bocavirus 1 (HBoV1) among 109 constitutionally healthy children, seroconversion measured by a standard IgG enzyme immunoassay (EIA) was the prime marker of acute infection, and signs and symptoms during sampling intervals were interpreted from hand-written questionnaires and study nurse notes (1). In that study, we found that acute HBoV1 infection was associated with upper respiratory tract illness (URTI) and acute otitis media. However, after discovery of 3 new human bocaviruses (HBoV2–4), we used a competitive second-generation IgG EIA to differentiate between type-specific and cross-reacting IgG responses and reassessed the etiologic associations of each virus in the same pediatric cohort. We found only a weak correlation of HBoV1 infection with acute otitis media and no correlation with URTI (2).
There are 2 reasons for this discrepancy. First, the competitive second-generation EIA generated a different set of HBoV1-infected children. A total of 27 children initially interpreted as having HBoV1 seroconversions had, on reassessment, HBoV2 or HBoV3 seroconversions (2). Second, after improved reevaluation of clinical symptoms of the entire replenished cohort by 3 of the co-authors, we found that URTI symptoms of 38 children were classified differently. Despite tight sampling, intervals of 3 and 6 months might still have been too long for clinical assessment for young children with numerous respiratory infections per year. The authors regret any inconvenience to readers.
Meriluoto M, Hedman L, Tanner L, Simell V, Mäkinen M, Simell S, Association of human bocavirus 1 infection with respiratory disease in childhood follow-up study, Finland.Emerg Infect Dis. 2012;18:264–71. DOIPubMedGoogle Scholar
Kantola K, Hedman L, Tanner L, Simell V, Mäkinen M, Partanen J, B-cell responses to human bocaviruses 1–4: new insights from a childhood follow-up study.PLoS One. 2015;10:e0139096. DOIPubMedGoogle Scholar
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
Exit Notification / Disclaimer Policy
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Meriluoto M, Hedman L, Tanner L, Simell V, Mäkinen M, Simell S, et al. Correction: Vol. 18, No. 2. Emerg Infect Dis. 2016;22(9):1695. https://doi.org/10.3201/eid2209.c12209
Meriluoto M, Hedman L, Tanner L, et al. Correction: Vol. 18, No. 2. Emerging Infectious Diseases. 2016;22(9):1695. doi:10.3201/eid2209.c12209.
Meriluoto, M., Hedman, L., Tanner, L., Simell, V., Mäkinen, M., Simell, S....Söderlund-Venermo, M. (2016). Correction: Vol. 18, No. 2. Emerging Infectious Diseases, 22(9), 1695. https://doi.org/10.3201/eid2209.c12209.
Correction: Vol. 18, No. 2
Volume 22, Number 9—September 2016
Article Views: 151
Data is collected weekly and does not include downloads and attachments. View data is from .
Click a source for Altmetric details
What is the Altmetric Attention Score?
The Altmetric Attention Score for a research output provides an indicator of the amount of attention that it has received. The score is derived from an automated algorithm, and represents a weighted count of the amount of attention Altmetric picked up for a research output.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Maria Söderlund-Venermo, Department of Virology, University of Helsinki, PO Box 21, Haartmaninkatu 3, Helsinki 00014, Finland